Finotti Alessia, Gambari Roberto
Department of Life Sciences and Biotechnology, Section of Biochemistry and Molecular Biology, University of Ferrara, 44121 Ferrara, Italy.
Research Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, 44121 Ferrara, Italy.
Noncoding RNA. 2025 Jan 12;11(1):3. doi: 10.3390/ncrna11010003.
The discovery of the involvement of microRNAs (miRNAs) in cystic fibrosis (CF) has generated increasing interest in the past years, due to their possible employment as a novel class of drugs to be studied in pre-clinical settings of therapeutic protocols for cystic fibrosis. In this narrative review article, consider and comparatively evaluate published laboratory information of possible interest for the development of miRNA-based therapeutic protocols for cystic fibrosis. We consider miRNAs involved in the upregulation of CFTR, miRNAs involved in the inhibition of inflammation and, finally, miRNAs exhibiting antibacterial activity. We suggest that antago-miRNAs and ago-miRNAs (miRNA mimics) can be proposed for possible validation of therapeutic protocols in pre-clinical settings.
在过去几年中，由于微小RNA（miRNA）可能作为一类新型药物用于囊性纤维化治疗方案的临床前研究，其在囊性纤维化（CF）中的作用被发现后受到了越来越多的关注。在这篇叙述性综述文章中，我们考量并比较评估了已发表的、对于开发基于miRNA的囊性纤维化治疗方案可能有价值的实验室信息。我们探讨了参与囊性纤维化跨膜传导调节因子（CFTR）上调的miRNA、参与炎症抑制的miRNA，以及最终具有抗菌活性的miRNA。我们建议，可以提出抗miRNA和模拟miRNA（miRNA模拟物），用于在临床前环境中对治疗方案进行可能的验证。
